Evaluation of persistence and safety in extending of injection period of ustekinumab from every 8 to 12 weeks in patients with ulcerative colitis
Not Applicable
Recruiting
- Conditions
- ulcerative colitis
- Registration Number
- JPRN-UMIN000044286
- Lead Sponsor
- Saitama Medical Center, Saitama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Not provided
Exclusion Criteria
Patients of contraindication of ustekinumab Patients with pregnancy or lactating Patients without informed consent Patients with previous or ongoing malignancy Patients with colectomy Patients who is not appropriate for this study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Persistence rate until 1 year
- Secondary Outcome Measures
Name Time Method